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Abstract 
Background: The magnitude of the effect of hepatitis C viral infection on survival is still not fully understood. The 
objective of this study was to determine whether the presence of hepatitis C viral antibodies in 1991 was associated 
with increased mortality 20 years later within a cohort of patients with substance use disorders. Secondary objectives 
were to determine other factors that were associated with increased mortality in the cohort.
Methods: A subset of a 1991 study cohort of patients who had presented for detoxification was reexamined 20 years 
later. The Social Security Death Index was queried to identify which of the original patients had died. Attributes of sur-
vivors and non-survivors were compared, with special attention to their hepatitis C status in 1991. The original study 
and this analysis were conducted in the chemical detoxification unit at Johns Hopkins Bayview (previously Francis 
Scott Key Hospital), an academic urban hospital. All participants met the criteria for alcohol or opioid dependence at 
the time of admission in 1991. The primary study outcome was 20-year mortality after initial admission in 1991, with a 
planned analysis of hepatitis C status.
Results: Twenty years after admission, 362 patients survived and 82 had died. Of the 284 patients who were hepatitis 
C positive, 228 survived (80 %). Of the 160 patients who were hepatitis C negative, 134 survived (84 %). This absolute 
risk increase of 4 % was not statistically significant (p = 0.37). Factors associated with increased mortality included 
male sex, white race, older age, and reported use of alcohol, cocaine, and illicit methadone. Binary logistic regres-
sion including hepatitis C status and these other variables yielded an adjusted odds ratio of 0.87 (95 % CI 0.49–1.55); 
(p = 0.64) for hepatitis C positive 20-year survival.
Conclusions: Hepatitis C positivity was not associated with a statistically significant difference in 20-year survival. The 
effect of the virus on mortality, if present, is small, relative to the effect of substance use disorders alone.
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Background
Hepatitis C has been recognized as the major cause of 
chronic hepatitis in people who inject drugs since 1992 
[1]. Epidemiologic studies have shown the prevalence 
of hepatitis C infection among drug users to be as high 
as 85–90  % in a variety of cities worldwide [2–4]. Most 
individuals who test positive for hepatitis C antibody 
have circulating hepatitis C virus, but 10–15 % clear the 
infection on their own [5]. It is estimated that about 50 % 
of infected individuals progress to chronic liver disease 
and 20 % progress to cirrhosis [6, 7]. The speed of pro-
gression appears multi-factorial, with progression accel-
erated by concurrent HIV infection and heavy alcohol 
use [8].
Since 1990, the treatment of hepatitis C has depended 
on the use of injectable interferon as the backbone of 
treatment [9, 10]. Related to the need for adherence, 
significant side effects and the intramuscular route of 
administration, a relatively small percentage of people 
who inject drugs have been considered for treatment, let 
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alone treated. However, recent advances in the treatment 
of hepatitis C have thrust attention to the consideration 
of treatment for most individuals with hepatitis C viremia 
[11–15]. This attention is likely to continue to expand as 
more treatments without interferon are approved over 
the next few years.
Along with the expanding pharmacotherapy for hepati-
tis C, there has come the recommendation for expanded 
screening for hepatitis C [16–21]. The CDC has advo-
cated for universal screening for hepatitis C for all Amer-
icans born between 1945 and 1964. This change in the 
screening guidelines stems from the fact that chronic 
hepatitis C infection can now be treated by several highly 
efficacious therapies [22, 23]. An important factor of 
these new treatment agents is their cost, ranging from 
20 to 80 thousand dollars per treatment attempt [24]. 
Given the high cost of treatment, many third-party pay-
ers currently triage their patients based on the extent of 
liver disease and the likelihood of death from hepatitis C 
related illness. Knowledge of the natural history of hepa-
titis C in patients with substance use disorders can aid in 
the complex decision of who and when to treat. People 
who inject drugs have a heavy burden of chronic hepatitis 
C as a population, due to the viral mode of transmission, 
and are also known to have a higher risk of early mor-
tality than the general population. The relative contribu-
tion of chronic hepatitis C infection in this population, 
compared to the contribution of other dangers such as 
overdose, suicide and homicide, is still not fully known 
[25]. Our study offers a prospective examination of this 
question.
In 1993, an early report on the prevalence of viral hepa-
titis C among alcohol and drug users showed the correla-
tion of anti-HCV positivity with elevated liver enzymes 
in that population [1]. The cohort was found to have a 
hepatitis C antibody prevalence of 63 % overall, and 86 % 
for those who reported ever using an illicit drug by injec-
tion. The arrival of the twenty-year anniversary of this 
study prompted us to investigate the 20-year all-cause 
mortality of the cohort, with specific attention to the 
presence or absence of anti-HCV positivity in 1991. In 
this study, we look at mortality of a subset of the original 
cohort, with a focus on whether or not hepatitis C infec-
tion was associated with higher mortality.
Methods
The original study was conducted on the Chemical 
Dependence Unit at Johns Hopkins Bayview Medical 
Center (then Francis Scott Key Medical Center), in Bal-
timore, Maryland, between November 1990 and May 
1991. Then and now, the unit has 26 inpatient beds and 
serves a mostly indigent population in the city of Balti-
more. Consecutive admissions were entered into the 
study. All patients met criteria for substance dependence. 
Demographic data were recorded and patient history 
related to substance use disorder, HIV infection, hepati-
tis and sexually transmitted infections was obtained. On 
admission to the unit, patients had blood testing which 
included tests for AST, ALT, hepatitis B surface antigen, 
hepatitis B surface antibody and rapid plasma regain 
(RPR) test for syphilis. All patients were offered HIV test-
ing. The presence of hepatitis C antibody (anti-HCV) was 
determined by a first generation enzyme linked immuno-
sorbent assay (Abbott Laboratories, Abbott Park, Illinois) 
that detects antibody to the C100-3 antigen. All positive 
serum samples were retested. Assays for hepatitis B were 
performed by enzyme immunoassay (Abbott Laborato-
ries). The presence of HIV antibody was determined by 
an enzyme linked immunosorbent assay (Genetic Sys-
tems, Seattle, Washington) and all positive samples were 
confirmed by Western blot (Dupont Laboratories, Wilm-
ington, Delaware).
Records from January 1991–May 1991 were located 
and 444 records were obtained. The Social Security 
Death Index was accessed to determine whether or not 
patients had died during the 20  years period since the 
date of admission. Causes of death were not determined. 
Prior to proceeding, anti-HCV status was chosen as a 
variable of interest in the data analysis. An initial bivari-
ate analysis was performed on the mortality groups, 
using Chi-squared or Fisher’s Exact tests for categorical 
variables and independent groups t tests for continuous 
variables, with significance levels set at p  <  0.05 using 
STATA 12.1. Anti-HCV status was then included in a 
regression analysis with all variables for which the mor-
tality group comparison yielded p values of 0.1 or less. 
Sex, race, age, history of STD, and histories of alcohol, 
cocaine and methadone use were found to have p values 
of 0.1 or less and were therefore included in the analysis. 
Using SPSS, odds ratios and confidence intervals for each 
of these variables were obtained. A binary logistic regres-
sion was then performed, which generated adjusted 
odds ratios for each of these variables. Attributes of the 
anti-HCV positive and anti-HCV negative cohorts were 
compared, using a Chi squared test in SPSS for categori-
cal variables, and an independent group t test for age. 
As a final step, a time-to-event plot was created, and the 
cumulative hazard function was calculated in SPSS, using 
death dates from the social security death index. This 
study was approved by the Johns Hopkins Institutional 
Review Board.
Results
The baseline demographics for the 20-year study cohort 
are shown in Table  1. There were 288 men and 156 
women. The majority were African American (63 %). Of 
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the 444 patients, 284 (63  %) were anti-HCV positive in 
1991. A history of cocaine use and heroin use was cor-
related with anti-HCV positivity in 1991. These results 
are described in the initial study and the subgroups of the 
found-records are presented in Table 1 [1].
The results of the query of the Social Security Death 
Index are presented in Table  2, which compares the 
attributes of 20-year survivors to non-survivors. After 
20 years, 82 of the 444 study participants were found to 
be deceased (18  %). The remaining patients were pre-
sumed to be alive. The mean ages of 20-year survivors 
and non-survivors in 1991 were 32.8 and 37.9, respec-
tively (p  <  0.001). Male patients had higher mortal-
ity than female patients, (23 vs. 10  %, p  =  0.001) and 
white patients in the cohort had greater mortality than 
black patients (30 vs. 14  %, p  <  0.001). Alcohol use 
(21 vs. 13  %, p  =  0.05) and illicit methadone use (31 
vs. 17  %, p  =  0.04) in 1991 were more weakly associ-
ated with death at 20  years. Surprisingly, a history of 
sexually transmitted disease was more common among 
survivors.
Hepatitis C antibody status from 1991 was compared 
between 20-year survivors and non-survivors. Patients 
who were anti-HCV positive in 1991 had a 20 % mortal-
ity, while anti-HCV negative patients had a 16  % mor-
tality. This difference was not statistically significant 
(p  =  0.37), and is illustrated in Fig.  1a. These data are 
then shown in Fig.  1b in comparison with the expected 
survivorship of the US general population of the same 
age, using data from the 1993 CDC death table [26]. Hep-
atitis B surface antigen positivity and hepatitis B surface 
antibody positivity were also not associated with mortal-
ity differences, but sample sizes may have been too small 
in some cases to provide adequate power for the compar-
isons. Liver enzymes were recorded in the initial study in 
three ranges. Those with lower liver enzymes in 1991 had 
a slightly greater chance of survival, but this too did not 
reach statistical significance.
The HCV negative and HCV positive cohorts are com-
pared in Table 3, to look for potential confounding vari-
ables. HCV positive patients were more likely to have 
been male, to have used cocaine and to have used illicit 
methadone. HCV positive patients were also older, on 
average, although HCV negative patients had a greater 
distribution of ages, including the youngest and oldest in 
the study.
Factors associated with decreased 20-year survival are 
compared in Table  4, and their unadjusted odds ratios 
are shown. Results of a binary logistic regression are also 
included, and displayed as adjusted odds ratios. Male sex 
and a history of illicit methadone use remain statistically 
significant after regression analysis. Age also remains sig-
nificant, with the odds of surviving decreasing slightly 
but significantly for each year of age of the individual at 
the start of the study. Again, hepatitis C positivity was not 
significantly associated with survival (OR 0.75, p = 0.29), 
and the non-significant association further diminished 
after binary logistic regression (AOR 0.87, p = 0.64).
In a time to event analysis, the survival curves for 
HCV positive and HCV negative patients were essen-
tially superimposable. The log rank test performed on the 
curve confirmed that the difference in the curves was not 
statistically significant (p = 0.410) (Fig. 2).
Discussion
Our current study was remarkable for two findings. 
The first was the overall increased mortality rate of this 
cohort of patients with substance use disorders, as com-
pared to that of the general population. The second 
finding was the lack of a statistical difference in mortal-
ity between those who were HCV positive in 1991, and 
those who were HCV negative at that time.
A query of the 1993 CDC mortality table shows that 
about 5000 out of 97,000 people aged 30–35 would 
Table 1 Baseline demographics of  cohort analyzed 
at 20 years
Number of patients 444
Mean age in 1991 33.7 SD 7.86
Number %
Gender
 Male 288 65
 Female 156 35
Race
 White 118 19
 Black 325 63
 Hispanic 1 0.2
History IDU 301 68
Drugs of abuse
 Alcohol 300 68
 Cocaine 315 71
 Heroin 284 64
 Methadone 39 9
 Benzodiazepines 80 18
 Marijuana 110 25
History of STD 175 39
HCV positive 284 64
HepBSAg positive 14 3
HepBSAb positive 142 32
HIV status
 HIV positive 46 10
 HIV negative 149 34
 HIV not tested 249 56
RPR positive 29 7
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have been expected to die in 20  years, a death rate of 
5.1  % [26]. Our observed death rate in the study popu-
lation was 18.4  %, indicating that the mortality rate of 
our cohort of patients with substance use disorders was 
substantially higher than that of the general US popula-
tion. Our results are concordant with previous stud-
ies showing premature death rates among patients with 
injection drug use [25]. Of the drugs studied, only illicit 
methadone use appeared to decrease survival. Cocaine 
use made hepatitis C positivity more likely, but in con-
cord with prior studies, showed no effect on survival [27].
The presence of the anti-HCV antibody in 1991 did not 
lead to a statistically significant increase in the 20-year 
mortality within this cohort. While our study did not 
have sufficient power to detect a small effect size, ample 
power was present for moderate or large effect sizes. It is 
therefore reasonable to conclude that the impact of hepa-
titis C infection on mortality, if present, was small. This 
study did not account for morbidity, so it is unknown 
whether cohort members were living with compensated 
or decompensated cirrhosis, or experienced other nega-
tive effects on their quality of life.
Our comparison of the attributes of the hepatitis C 
negative and hepatitis C positive cohorts shows that the 
hepatits C positive patients were more likely to have 
been male, to be older, and to have used illicit metha-
done, three factors which we would expect to make them 
more likely to die, given the data from this study. These 
attributes of the hepatitis C positive cohort are probably 
responsible for the diminished association of HCV posi-
tivity and mortality after the regression analysis. The fact 
that hepatitis C positive patients were more likely to have 
used cocaine likely made little difference in their survival. 
The fact that illicit use of methadone was associated with 
decreased survival may have been incidental but may 
also be related to the medication’s potential for respira-
tory depression and cardiac arrhythmias [28, 29]. Hazard 
from both of these factors may have been increased in 
patients using methadone outside of a supervised setting 
[30, 31].
Table 2 Mortality at 20 years, by subgroup
Demographic Alive Deceased % deceased, % P
Totals 362 82 18
Age mean, years 32.8 37.9 <0.0001
Gender
 M 222 66 23
 F 140 16 10 0.001
Race*
 White 83 35 30
 Black 278 47 14 0.001
Hx IDU
 Yes 244 57 19
 No 118 25 17 0.72
Drugs of abuse
 Alcohol
  Yes 237 63 21
  No 125 19 13 0.05
Cocaine
 Yes 263 52 17
 No 99 30 23 0.1
Heroin
 Yes 233 51 18
 No 129 31 19 0.71
Methadone
 Yes 27 12 31
 No 335 70 17 0.04
Benzodiazepines
 Yes 61 19 24
 No 301 63 17 0.18
Marijuana
 Yes 90 20 18
 No 272 62 19 0.93
Hx STD
 Yes 152 23 13
 No 210 59 22 0.02
Hep C Ab
 Positive 228 56 20
 Negative 134 26 16 0.37
Hep BSAg
 Positive 10 4 29
 Negative 352 78 18 0.32
HepBSab
 Positive 115 27 19
 Negative 247 55 18 0.84
HIV
 Positive 23 7 23
 Negative* 339 74 18 0.46
RPR
 Positive 23 29 56
 Negative 339 415 55 0.75
AST
Table 2 continued
Demographic Alive Deceased % deceased, % P
 <31 210 39 16
 >31 and <60 86 23 21 0.21
 >60 66 20 23
ALT
 <31 193 39 17
 >31 and <60 91 23 20 0.64
 >60 78 20 20
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Previous studies that have examined the mortality of 
patients with active hepatitis C virus tend to show little 
impact on mortality early in the disease course. Grady, 
et al. found 10-year survivals to be similar between seron-
egative and seropositive patients for the first 10  years, 
and suggested divergence around 20  years [32]. Gibson 
et  al., similarly only showed increases in liver-related 
deaths past the 20 year mark, while Grebely et al. show 
the effect more pronounced only in patients over 50 years 
of age [33, 34]. Kieland et  al. similarly show no change 
in mortality until three decades out from infection, in 
patients with an age greater than 50 [35]. Lee et al. doc-
umented a substantially greater hepatitis-C associated 
mortality, although their study did not focus specifi-
cally on patients with substance use disorders [36]. Our 
study serves to validate the emerging trend that hepati-
tis C positivity among patients with substance use disor-
ders does not manifest a mortality difference for at least 
the first 20 years, and demonstrates this trend within an 
urban population in the United States.
The impact of hepatitis C virus specifically on patients 
with substance use disorders was studied by Evans et al. 
in San Francisco, CA, in a manner very similar to the 
one that we employed [37]. Similar to our results, they 
demonstrated that intravenous drug use itself was a risk 
factor for higher mortality; hepatitis C positivity only 
showed a non-significant trend towards higher mortality. 
Larney et al. studied hepatitis C related mortality among 
veterans with opioid use disorder and found no differ-
ence in overall mortality, although hepatitis C patients 
were more likely to a have a liver-related cause of death 
[38]. In an international study of three large national 
medical systems, Aspinal et al. document that both drug 
overdose and all-cause liver mortality were important 
contributors to mortality among patients with hepatitis 
C infection [39]. Hayashi et al. did a prospective study of 
patients with intravenous drug use in Vancouver, and did 
not find any increased liver mortality in the absence of 
HIV [40]. Several studies do indicate that HIV/HCV co-
infection hastens the progression of liver disease [41–43].
Our study had several limitations. Cause of death was 
unavailable from the social security death index that we 
queried. As such, we could not make inferences about the 
frequency of liver-related mortality. At the time of the 
study in 1991, HCV RNA tests were not yet common-
place, and as such, there was no way to know which of 
the anti-HCV positive patients in the cohort had experi-
enced spontaneous clearance. It is reasonable to assume 
that this would have constituted 10–15  % of the group. 
Another important limitation of this study is the fact 
that the HIV status of 56 % of the sample is unknown. Of 
those who were tested, 23 % were positive for HIV, mak-
ing it a notable comorbidity within the cohort that could 
have accounted for some of its increased mortality rate as 
compared to the general population. Our study was also 
vulnerable to information bias, as it is possible that some 
of the cohort-members counted in the anti-HCV negative 
group may have contracted HCV over the 20 year period 
of the study. Conversely, some members of the anti-HCV 
positive group may have obtained HCV treatment. It is 
Fig. 1 a Anti-HCV positivity did not confer a statistically significant 
20-year mortality increase. b Comparison of deaths among IV drug 
users, compared to US General Population
Table 3 Attributes of  hepatitis C negative and  positive 
cohorts
* p value computed by Chi-square analysis






Female 70 (0.45) 86 (0.55) 156 0.004
Male 90 (0.31) 198 (0.69) 288
Nonwhite 123 (0.38) 203 (0.62) 326 0.217
White 37 (0.31) 81 (0.69) 118
No alcohol 51 (0.35) 93 (0.65) 144 0.851
Alcohol 109 (0.36) 191 (0.64) 300
No cocaine 66 (0.51) 63 (0.49) 129 <0.001
Cocaine 94 (0.3) 221 (0.7) 315
No illicit  
methadone
152 (0.38) 253 (0.62) 405 0.034
Illicit methadone 8 (0.21) 31 (0.79) 39
Did not report  
STD History
94 (0.35) 175 (0.65) 269 0.552
Reported STD 
history
66 (0.38) 109 (0.62) 175
Mean age (years) 32.48 34.43 N/A 0.028**
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also possible that some of the patients were deceased but 
not reported to the Social Security administration, but 
this should not bias the results.
Our study has implications for health policy-related 
questions. Current medical practice has begun to shift 
attention toward stewardship and the allocation of medi-
cal resources, with campaigns such as Choosing Wisely 
gaining increased popularity [44]. Given a system with 
limited financial resources, it may be reasonable to ques-
tion which therapies would provide the greatest health 
benefit to patients with substance use disorders. The 
average cost per treatment episode for outpatient sub-
stance use disorder is $2000–7000 [45]. The cost of new 
oral treatment for hepatitis C infection has been esti-
mated at $84,000 per 12-week course of therapy [24]. 
Our study suggests that substance use disorders alone 
increase mortality, a finding that is consistent with prior 
research [46–48]. It does not, however, support the idea 
that hepatitis C virus was responsible for a significant 
fraction of that mortality. Although in a perfect system 
all patients would be treated for both, our study sug-
gests that younger patients with substance use disorders 
may derive more mortality benefit from addiction treat-
ment than they would derive from treatment of hepati-
tis C virus. This effect may shift over time as patients get 
older. Further research is necessary to establish which 
Table 4 Regression analysis of hepatitis C viral status and factors associated with decreased 20-year survival
Factor OR CI (P value) AOR CI (P value)
Hepatitis C antibody (positive) 0.75 0.45–1.27 (0.29) 0.87 0.49–1.55 (0.64)
Sex (male) 0.39 0.22–0.71 (<0.01) 0.51 0.27–0.95 (0.03)
Age 0.93 0.31–0.96 (<0.01) 0.95 0.92–0.98 (<0.01)
Race (white) 0.39 0.24–0.64 (<0.01) 0.51 0.29–0.89 (0.02)
Alcohol use was present 0.58 0.33–1.02 (0.06) 0.76 0.41–1.4 (0.38)
Cocaine use was present 1.47 0.88–2.44 (0.14) 0.99 0.54–1.79 (0.96)
Illicit methadone use was present 0.46 0.22–0.96 (0.04) 0.46 0.21–0.99 (0.05)
History of sexually transmitted disease (true) 1.95 1.15–3.33 (0.01) 1.70 0.95–3.03 (0.07)
Fig. 2 Time to event analysis of mortality for hepatitis C positive and negative patients
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patients would be best served by treatment for one or 
both conditions.
Conclusions
Hepatitis C antibody positivity was not associated with a 
statistically significant change in 20 years mortality among 
a cohort of patients with substance use disorders within 
an urban setting. The overall mortality of the cohort was 
higher than that of the general population in both hepati-
tis C positive and hepatitis C negative patients. The rela-
tive effect of hepatitis C status on mortality, if present, is 
likely quite small in comparison to the effect of substance 
use disorder within the population studied.
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